Shenzhen DIVBIO Pharmaceutical Co., Ltd.

DIVBIO Pharmaceutical Co., Ltd. ("DIVBIO"), headquartered in Shenzhen, China, is a biotechnology enterprise focused on TIDES ( Peptides and Oligonucleotides ) field. DIVBIO strives to establish global leadership based on its pioneering peptide and oligonucleotide modification technology platforms.

Since its establishment, DIVBIO has developed a pioneering peptide and oligonucleotides modification technology platform and AIDD platform integrated with IPD management capabilities. These platforms enable the development of peptide-drug conjugates (PDCs), GLP-1 and a broad portfolio of both preventive and therapeutic pharmaceutical products.

Different peptide structures: linear peptides, branched peptides, asymmetrically branched peptides, cyclic peptides.

Different scales: single peptide, bulk peptides, peptide libraries.

Antigen peptides: conjugation with proteins such as KLH, BSA, OVA, etc.

Custom aliquoting: Peptides are aliquoted according to customer requirements (free aliquoting for up to 10 tubes per peptide).

Standard linear peptides: Milligram to kilogram scale.

Purity ranges: Crude, desalted, >75%, >80%, >85%, >90%, >95%, >98%.

Modified peptides: Lipopeptides, phosphorylation (Ser, Thr, Tyr), cyclization (amide bond cyclization, disulfide bond cyclization), fluorescent labeling (FAM, etc.), biotin labeling (Biotin), multiple antigen peptides (MAP), etc.

High quality: Provides MS, HPLC spectra, and detailed analysis reports. Additionally, peptide content analysis reports, amino acid analysis reports, endotoxin testing reports, and peptide solubility recommendations can be provided upon request.

Comprehensive modifications: Over 400 modifications available, including fluorescent modifications, disulfide bond cyclization, amide bond cyclization, stapled peptides, isotope labeling, FRET (fluorescence resonance energy transfer) pairs, C-terminal AMC modifications, etc.

Advanced technology: Capable of synthesizing peptides up to 80 amino acids in length. Leveraging the company's unique expertise in small-molecule liquid-phase synthesis, we combine solid-phase and liquid-phase methods to tackle challenging and complex peptides.

High success rate: Success rate >95%.

Strict confidentiality: Non-disclosure agreements (NDAs) can be signed.